GPT Healthcare Limited — PPTs, 23-05-2025: Investor Presentation

1. Financial Highlights:

GPT Healthcare reported revenue of Rs 407.1 Cr, up 1.7% YoY. EBITDA slipped 1.3% to Rs 91.9 Cr, with a margin of 22.1%. PAT grew 4.6% to Rs 50 Cr, maintaining a 12.0% margin. ARPOB increased 13% to Rs 37,180, and ALOS improved 10% to 3.54 days. ROE and ROCE stood at 20.1% and 23.5%. The net cash position is reflected in net debt to equity of -0.32x. Operating cash flow was strong at Rs 84.5 Cr. Capex in PPE remained steady at Rs 202.6 Cr, supported by a healthy equity base of Rs 248 Cr.

2. Strategic Initiatives & Growth Drivers:

The company is diversifying its case mix while targeting 1,000 beds in two years, focusing on Tier I & II cities in Eastern India. Key launches include robotic knee surgeries at Howrah and Radiation Oncology in Agartala (near commissioning). Digital investments continue with the ILS-MyHealth app and HMIS electronic records. A new 158-bed hospital in Raipur operates on a rental model with Rs 74 Cr capital deployed.

3. Business Developments:

Ramp-up plans are underway to reach 70-75% occupancy at Agartala and Howrah. The Raipur hospital enhances quaternary care with advanced diagnostics and oncology. Over 500 robotic surgeries completed at Salt Lake and Howrah hospitals highlight their surgical excellence. A 150-bed hospital in Jamshedpur (Rs 75 Cr investment) is planned for FY27.

4. Market Position & Competitive Advantage:

Operating 719 beds across five multispecialty hospitals in Eastern India with key accreditations (NABH, NABL), GPT Healthcare leverages mid-sized hospitals in populous markets for strong returns. Rapid EBITDA breakeven in recent hospitals (Dum Dum in 10 months, Howrah in 8 months) demonstrates operational efficiency. Scalable digital platforms and diversified specialties reduce single specialty risks.

5. Investor Implications:

Consistent revenue growth, stable margins, and robust cash flows signal positive growth potential. Expansion in new geographies and tech-driven services supports volume and ARPOB gains. Execution risks center on ramping up occupancy and new hospital commissioning. The company’s disciplined capital use and attractive returns make it a compelling regional healthcare play for investors.